OR WAIT null SECS
June 23, 2021
With technological advancements in affinity tuning and real-time tracking of CAR-T cells, the hope is that CAR-T therapy can be effectively applied to treating solid tumors, improve patient outcomes, and avoid the toxicities seen with certain treatments in the clinic.
June 09, 2021
How Gilead readied remdesivir for the COVID challenge.
Inside Regeneron’s monoclonal antibody development to treat COVID.
Past lessons, strong resolve, and complex coordination propel J&J’s vaccine efforts.
Thrust into a commercial-stage company in just months, Moderna moves full steam ahead.
College roommates, industry partnerships help bring Pfizer vaccine to fruition.
June 08, 2021
The recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.
May 27, 2021
The field of longevity therapeutics — with the goal “of not just adding years to life but adding life to years” — is already disrupting the medical industry, writes Marco Quarta.
May 14, 2021
Annovis Bio's Maria L. Maccecchini, Ph.D., talks about why she, as a scientist and biotech company entrepreneur, became focused on protecting nerve cells in the brain and in the body, as a way to treat neurodegenerative disease.
April 27, 2021
Pascal Descargues, Ph.D., founder of Genoskin, talks about how the company is responding to the US government’s push to help pharma and biotech leaders speed clinical drug development and testing.
